Home › Sakit ng Graft-versus-Host › Pennsylvania
Pag-aaral pangklinika para sa Sakit ng Graft-versus-Host sa Pennsylvania
6 pag-aaral para sa Sakit ng Graft-versus-Host ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.
Mga Lungsod sa Pennsylvania
Opisyal na teksto ng pag-aaral (English)
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07565220A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Nagre-recruitPhase 2
Edad 2 pataas · Lahat ng kasarian · Na-update Hun 16, 2026 · NCT04710576A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
- University of Pittsburgh Medical Center (Data Collection Only), Pittsburgh
Nagre-recruitPhase 2
Edad 4 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT05675930A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Pennsylvania, Philadelphia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 20, 2026 · NCT06615050Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- Penn State Cancer Institute, Hershey
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 3, 2026 · NCT06926595A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- UPMC Hillman Cancer Center, Pittsburgh
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT06619561Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.